Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of azetukalner in epilepsy
NL-OMON59098Phase 3Recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azetukalner in epilepsy, Focal onset seizure and generalized tonic-clonic seizure (GTCS), sponsored by Xenon Pharmaceuticals. Primary endpoints: Long-term safety and tolerability and Clinical safety assessments. Started Aug 2026; status: recruiting.
02
Drugs
azetukalner
03
Conditions
epilepsyFocal onset seizuregeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on NL-OMON59098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59098.